Original-Research: Cardiol Therapeutics Inc – from First Berlin Equity Research GmbH
22.11.2024 / 11:05 CET/CEST
Dissemination of a Research, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.
Classification of First Berlin Equity Research GmbH to Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera reiterated his BUY rating and maintained his USD 8.50 price target.
Abstract:
Cardiol Therapeutics (Cardiol) announced excellent final data including data for the extension period (EP) from the phase II open-label pilot US study (MAvERIC-Pilot) of its lead drug candidate CardiolRx for the treatment of recurrent pericarditis (RP) in 27 patients. The findings were presented at the American Heart Association Scientific Sessions 2024 by one of the lead investigators, Dr S. Allen Luis, Co-Director of the Pericardial Diseases Clinic at the Mayo Clinic. The data showed that the significant improvements in both pericarditis pain and inflammation seen in the reported results of the primary endpoint at 8 weeks were maintained throughout the 26-week EP of the study. Importantly, during the EP, where patients transitioned from combination therapy (CardiolRx plus standard of care) to CardiolRx monotherapy, 71% remained free from recurrence, demonstrating the drug candidate’s efficacy. Overall, the treatment was well tolerated, with 89% of participants completing the study and adherence reported at 95%. These findings clearly support the progression of CardiolRx into phase II/III MAvERIC-2 and phase III MAvERIC-3 trials, positioning it as a promising, non-immunosuppressive therapeutic option for patients with RP. We thus expect the company to report positive headline results from the phase II study for acute myocarditis (AM) by early 2025. We believe that investors have overlooked the significant recent progress made in Cardiol’s pipeline, which has left the company significantly undervalued at current levels. We reiterate our Buy recommendation at an unchanged price target of USD8.50.
First Berlin Equity Research has published a research update on Cardiol Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera reiterates his BUY recommendation and reiterates his price target of USD 8.50.
Summary:
Cardiol Therapeutics (Cardiol) announced excellent final data, including extension period (EP) data, from the US Phase II open-label pilot study (MAvERIC Pilot) for its lead drug candidate CardiolRx for the treatment of recurrent pericarditis (RP). 27 patients known. The results were presented at the American Heart Association Scientific Sessions 2024 by one of the principal investigators, Dr. S. Allen Luis, co-director of the pericardial disease clinic at the Mayo Clinic. Data showed that the significant improvements in pericarditis pain and inflammation seen in the reported primary endpoint results at 8 weeks were maintained throughout the 26-week EP of the study. Importantly, during the EP, in which patients were switched from combination therapy (CardiolRx plus standard treatment) to CardiolRx monotherapy, 71% of patients remained relapse-free, demonstrating the effectiveness of the drug candidate. Overall, the treatment was well tolerated: 89% of participants completed the study and adherence was 95%. These results clearly support inclusion of CardiolRx in the Phase II/III MAvERIC-2 and Phase III MAvERIC-3 trials and position it as a promising non-immunosuppressive treatment option for patients with RP. We therefore expect the company to report positive results from the Phase II study for acute myocarditis (AM) in early 2025. We believe investors have overlooked recent significant advances in Cardiol’s pipeline, leaving the company significantly undervalued at current levels. We reiterate our Buy recommendation with an unchanged price target of USD8.50.
Regarding the mandatory information in accordance with Section 85 Paragraph 1 Sentence 1 WpHG and the exclusion of liability, see the complete analysis.
You can download the research here: http://www.more-ir.de/d/31423.pdf
Contact for questions:
First Berlin Equity Research GmbH
Mr Gaurav Tiwari
Tel.: +49 (0)30 809 39 686
web: www.firstberlin.com
Email: g.tiwari@firstberlin.com
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
2036745 22.11.2024 CET/CEST
**What potential market share and revenue opportunities does CardiolRx target in the context of the current treatment landscape for recurrent pericarditis, and how might its monotherapy efficacy impact these projections?**
## Interview: Cardiol Therapeutics – A Promising Future in Cardiac Care?
**Introduction:**
Welcome to World-Today-News. Today, we delve into the exciting advancements in the treatment of recurrent pericarditis and acute myocarditis with Cardiol Therapeutics Inc. We are joined by two distinguished guests:
* **Dr. Emily Carter**, Professor of Cardiology at Stanford University, and a leading expert in pericardial diseases.
* **Mr. John Thompson**, Senior Healthcare Analyst specializing in cardiology and biotechnology investments.
**Section 1: Understanding the Needs**
* **Dr. Carter, can you provide our viewers with a brief overview of recurrent pericarditis and its impact on patients’ lives? What are the current treatment challenges?**
* **Mr. Thompson, how significant is the unmet need for effective and non-immunosuppressive treatment options for recurrent pericarditis in the current market?**
**Section 2: CardiolRx and the MAvERIC Trials**
* **Dr. Carter, what is your assessment of the Phase II open-label pilot study results for CardiolRx? How do these findings compare to existing therapies for RP?**
* **Mr. Thompson, can you elaborate on the importance of CardiolRx’s demonstrated efficacy as a monotherapy? What does this mean for patients and potential market penetration?**
**Section 3: Looking Ahead – MAvERIC-2, MAvERIC-3, and Acute Myocarditis**
* **Dr. Carter, what are your expectations for the upcoming MAvERIC-2 and MAvERIC-3 trials? What further insights do we hope to gain from these studies?**
* **Mr. Thompson, based on First Berlin Equity Research’s analysis and your own industry knowledge, what is your outlook for Cardiol Therapeutics moving forward? What are the key milestones investors should watch for in the next two years?**
**Section 4: Investor Perspective**
* **Mr. Thompson, First Berlin Equity Research has issued a ”BUY” recommendation with a price target of USD 8.50 for Cardiol Therapeutics. What factors are driving this optimistic outlook? Do you believe the market is currently undervaluing the company’s potential?**
* **Dr. Carter, what message would you give to patients who are looking to learn more about promising new treatments for pericarditis and myocarditis? Where can they find reliable and up-to-date information?**
**Conclusion:**
Thank you both for sharing your invaluable expertise. The findings on CardiolRx present encouraging news for patients suffering from recurrent pericarditis and acute myocarditis. As research continues, we eagerly await the outcomes of future trials. Stay tuned to World-Today-News for more updates on this exciting medical development.
**Note:** This interview framework is designed to be flexible. The specific questions and flow of the conversation can be adjusted based on the guests’ responses and the desired depth of discussion.
